Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Orthop. Jun 18, 2021; 12(6): 395-402
Published online Jun 18, 2021. doi: 10.5312/wjo.v12.i6.395
Table 1 Demographic factors for patients included in this study

No. of IIM patients
No. of control patients
P value
Total number of patients545545
Female patients74.90%74.90%1.000
Age (yr)
≤ 6424.4%23.6%
65-6925.0%24.1%
70-7419.1%19.7%0.993
75-7917.1%18.1%
80-8411.4%11.2%
≥ 853.1%3.4%
Region
Midwest23.1%26.8%
Northeast18.5%21.5%0.1851
South41.3%36.9%
West17.1%14.9%
Table 2 Additional comorbidities for patients included in this study
Comorbidity
Proportion of IIM patients without comorbidity
Proportion of control patients without comorbidity
P value
AIDS0.59%1.74%0.479
Congestive heart failure29.66%30.68%1.000
Depression37.3%40.52%0.402
Diabetes mellitus144.35%58.61%0.000
SUD–Drugs6.31%7.96%0.910
SUD–Alcohol2.35%4.2%0.716
Hypertension89.43%92.19%0.112
Hypothyroidism42.44%38.21%0.059
Liver disease12.92%12.45%0.355
Lymphoma3.38%4.63%1.000
Metastatic cancer5.14%6.8%0.901
Neurological disease13.07%13.6%0.742
Pulmonary disease145.96%55.86%0.001
PVD130.1%30.54%0.008
Table 3 Results of multivariate regression analysis to evaluate the relative risk of complications in patients with idiopathic inflammatory myopathies compared with controls following total hip arthroplasty
Complication

OR (95%CI)
P value
Acute kidney injury0.0341.035 (0.817-1.311)0.778
Cardiac arrest0.3151.370 (0.712-2.636)0.346
Deep vein thrombosis0.4231.526 (0.524-4.443)0.438
Nerve injury-0.9660.381 (0.039-3.687)0.405
Pneumonia10.3761.456 (1.170-1.812)0.001
Pulmonary embolism10.3781.460 (1.026-2.077)0.035
Urinary tract infection0.1231.131 (0.931-1.374)0.215
Wound disruption-0.2490.780 (0.485-1.253)0.304
Hematoma1-0.5420.582 (0.406-0.833)0.003
Transfusion0.0601.062 (0.861-1.310)0.573
Capsulitis0.3551.426 (0.952-2.137)0.085
Infection-0.3420.71 (0.442-1.139)0.156